Revolution Medicines D
D
RVMD
172.280
USD
-4.01
(-2.27%)
Post Trading·172.020USD-0.260(-0.15%)
Last updated: · Delayed 15 min
Revolution Medicines current ratioWhat is the current ratio? The current ratio is current assets divided by current liabilities: whether what a company will turn into cash within a year covers what it owes within a year.
Revolution Medicines's current ratio is 8.36: current assets of 3.98B USD against current liabilities of 475.67M USD due within a year.
- Today
- 8.36
- Average, 5 years
- 11.36
- Low, 5 years
- 6.80
- High, 5 years
- 18.45
Current ratio = current assets ÷ current liabilities = 3.98B ÷ 475.67M = 8.36
Current ratio
Total current assets
Total current liabilities
Current assets over current liabilities at each quarter end: above 1, what falls due within a year is covered by what turns into cash within a year.
Current ratio by year and by quarter
| Fiscal year | Period ending | Current ratio | Total current assets | Total current liabilities |
|---|---|---|---|---|
| Today | 8.36 | 3.98B | 475.67M | |
| FY2025 | 31 Dec 2025 | 7.14 | 2.08B | 290.42M |
| FY2024 | 31 Dec 2024 | 14.20 | 2.33B | 163.91M |
| FY2023 | 31 Dec 2023 | 13.06 | 1.88B | 143.85M |
| FY2022 | 31 Dec 2022 | 10.65 | 660.19M | 61.98M |
| FY2021 | 31 Dec 2021 | 9.77 | 589.77M | 60.35M |
| FY2020 | 31 Dec 2020 | 9.63 | 454.12M | 47.18M |
| FY2019 | 31 Dec 2019 | 3.11 | 133.98M | 43.05M |
| FY2018 | 31 Dec 2018 | 2.80 | 85.43M | 30.55M |
| FY2017 | 31 Dec 2017 | 1.24 | 9.44M | 7.60M |
| Quarter | Period ending | Current ratio | Total current assets | Total current liabilities |
|---|---|---|---|---|
| Q3 FY2026 | 30 Sept 2026 | 8.36 | 3.98B | 475.67M |
| Q2 FY2026 | 30 Jun 2026 | 11.38 | 4.03B | 354.06M |
| Q1 FY2026 | 31 Mar 2026 | 6.80 | 1.97B | 289.60M |
| Q4 FY2025 | 31 Dec 2025 | 7.14 | 2.08B | 290.42M |
| Q3 FY2025 | 30 Sept 2025 | 8.05 | 1.98B | 245.62M |
| Q2 FY2025 | 30 Jun 2025 | 11.79 | 2.18B | 184.53M |
| Q1 FY2025 | 31 Mar 2025 | 13.46 | 2.13B | 158.60M |
| Q4 FY2024 | 31 Dec 2024 | 14.20 | 2.33B | 163.91M |
| Q3 FY2024 | 30 Sept 2024 | 14.24 | 1.58B | 110.86M |
| Q2 FY2024 | 30 Jun 2024 | 15.42 | 1.62B | 105.33M |
| Q1 FY2024 | 31 Mar 2024 | 18.45 | 1.73B | 93.72M |
| Q4 FY2023 | 31 Dec 2023 | 13.06 | 1.88B | 143.85M |
| Q3 FY2023 | 30 Sept 2023 | 9.64 | 824.47M | 85.54M |
| Q2 FY2023 | 30 Jun 2023 | 11.81 | 922.09M | 78.06M |
| Q1 FY2023 | 31 Mar 2023 | 16.89 | 922.75M | 54.64M |
| Q4 FY2022 | 31 Dec 2022 | 10.65 | 660.19M | 61.98M |
| Q3 FY2022 | 30 Sept 2022 | 9.21 | 675.11M | 73.27M |
| Q2 FY2022 | 30 Jun 2022 | 7.60 | 483.05M | 63.54M |
| Q1 FY2022 | 31 Mar 2022 | 9.30 | 534.34M | 57.46M |
| Q4 FY2021 | 31 Dec 2021 | 9.77 | 589.77M | 60.35M |
| Q3 FY2021 | 30 Sept 2021 | 12.02 | 623.54M | 51.89M |
| Q2 FY2021 | 30 Jun 2021 | 14.43 | 661.01M | 45.80M |
| Q1 FY2021 | 31 Mar 2021 | 15.94 | 697.41M | 43.76M |
| Q4 FY2020 | 31 Dec 2020 | 9.63 | 454.12M | 47.18M |
| Q3 FY2020 | 30 Sept 2020 | 11.39 | 482.90M | 42.38M |
| Q2 FY2020 | 30 Jun 2020 | 7.78 | 340.38M | 43.74M |
| Q1 FY2020 | 31 Mar 2020 | 8.72 | 362.09M | 41.51M |
| Q4 FY2019 | 31 Dec 2019 | 3.11 | 133.98M | 43.05M |
| Q3 FY2019 | 30 Sept 2019 | 3.86 | 149.12M | 38.64M |
| Q2 FY2019 | 30 Jun 2019 | — | — | — |
| Q1 FY2019 | 31 Mar 2019 | — | 69.59M | 0.00 |
| Q4 FY2018 | 31 Dec 2018 | 2.80 | 85.43M | 30.55M |
Figures in USD. A quarter's revenue, net income and dividends are those of its last four quarters.
See also:Market cap,ROE (return on equity),Debt to equity,All ratios
Common questions about Revolution Medicines's current ratio
Source: Financial Modeling PrepVerified against SEC filings